Literature DB >> 12953149

Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression.

C-M Shih1, Y-C Shiau, J-J Wang, S-T Ho, A Kao.   

Abstract

In vitro studies have shown that technetium-99m tetrofosmin (Tc-99m TF) is a transport substrate for the P-glycoprotein (Pgp) pump. Therefore, Tc-99m TF uptake of tumors can be used to predict chemotherapy response in lung cancers. However, whether lung resistance-related protein (LRP) expression affects tumor accumulation and efflux of Tc-99m TF in lung cancers is not known. Our aim was to use Tc-99m TF uptake of tumors to predict paclitaxel-based chemotherapy response of non-small cell lung cancer (NSCLC) and to compare Pgp or LRP expression. Twenty patients with advanced NSCLC received Tc-99m TF chest images before Taxol-based chemotherapy was used in this study. The chemotherapy response was evaluated by clinical and radiological methods in the third month after completion of treatment. No significant differences of prognostic factors (age, sex, body weight loss, performance status, tumor size, tumor stage, and tumor cell type) were found between the patients with good and those with poor responses. Early and delayed tumor/normal lung (T/L) uptake ratios were calculated on Tc-99m TF chest images. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to detect Pgp and LPR expressions. The early and delayed T/L uptake ratios of 10 patients with good response were significantly higher than those of the other 10 patients with poor response. Significantly higher early and delayed T/L uptake ratios were found in patients with negative than those with positive Pgp expression ( p < 0.05). However, no significant differences of early and delayed T/L uptake ratios were found between patients with negative and positive LRP expressions ( p > 0.05). We found that Tc-99m TF imaging could accurately predict Taxol-base chemotherapy response. In addition, the Tc-99m TF tumor uptake was related to Pgp but not LPR expression in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953149     DOI: 10.1007/s00408-003-1011-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  21 in total

Review 1.  MDR1 gene expression in solid tumours.

Authors:  L J Goldstein
Journal:  Eur J Cancer       Date:  1996-06       Impact factor: 9.162

2.  Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.

Authors:  C H Kao; J F Hsieh; S C Tsai; Y J Ho; S P Changlai; J K Lee
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

3.  Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.

Authors:  L Kostakoglu; P Kiratli; S Ruacan; M Hayran; S Emri; E L Ergün; C F Bekdik
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

Review 4.  Visualization of multidrug resistance in vivo.

Authors:  N H Hendrikse; E J Franssen; W T van der Graaf; W Vaalburg; E G de Vries
Journal:  Eur J Nucl Med       Date:  1999-03

5.  Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer.

Authors:  J Zhou; K Higashi; Y Ueda; Y Kodama; D Guo; F Jisaki; A Sakurai; T Takegami; S Katsuda; I Yamamoto
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

6.  Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution.

Authors:  S H Cheng; W Lam; A S Lee; K P Fung; R S Wu; W F Fong
Journal:  Toxicol Appl Pharmacol       Date:  2000-04-15       Impact factor: 4.219

7.  Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.

Authors:  M Kitazono; T Sumizawa; Y Takebayashi; Z S Chen; T Furukawa; S Nagayama; A Tani; S Takao; T Aikou; S Akiyama
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

Review 8.  Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.

Authors:  P A Francis; M G Kris; J R Rigas; S C Grant; V A Miller
Journal:  Lung Cancer       Date:  1995-04       Impact factor: 5.705

9.  The drug resistance-related protein LRP is the human major vault protein.

Authors:  G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

10.  Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.

Authors:  M A Izquierdo; R H Shoemaker; M J Flens; G L Scheffer; L Wu; T R Prather; R J Scheper
Journal:  Int J Cancer       Date:  1996-01-17       Impact factor: 7.396

View more
  5 in total

Review 1.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

Review 2.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

3.  A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Authors:  Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; Frank M Balis; Aradhana M Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-11-16       Impact factor: 12.531

4.  (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.

Authors:  Bin Chen; Guoqing Zhao; Qingjie Ma; Bin Ji; Tiefeng Ji; Hua Xin; Shi Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 5.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.